

AMENDMENTS TO THE CLAIMS

1. - 2. (Canceled)

3. (Currently Amended) ~~Factor A~~ a factor X analogue, wherein the sequence Leu-Thr-Arg-Ile-Val-Gly (SEQ ID NO: 1) of the activation site of native factor X is replaced with the sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9).

4. - 8. (Canceled)

9. (Previously Presented) A method of treating coagulopathy resulting from a deficiency in factor VIII, in factor IX or in factor XI in a subject in need thereof comprising administering to said subject a procoagulant medicinal product comprising a factor X analogue according to claim 3.

10. (Previously Presented) The method according to Claim 9, wherein said coagulopathy is haemophilia type A or haemophilia type B.

11. - 17. (Canceled)

18. (Currently Amended) ~~Factor A~~ a factor Xa analogue which can be obtained by cleavage of a factor X analogue according to Claim 3, by thrombin.

19. (Currently Amended) ~~Nucleie~~ A nucleic acid molecule encoding a factor X analogue according to Claim 3.

20. (Currently Amended) ~~Recombinant~~ A recombinant vector, comprising a nucleic acid molecule according to Claim 19.
21. (Currently Amended) ~~Host~~ A host cell genetically transformed with a nucleic acid molecule according to Claim 19.
22. (Previously Presented) A procoagulant medicinal product comprising a factor X analogue according to Claim 3.
23. - 38. (Canceled)